Search Results

All News July 20th, 2023 Global Startup Heat Map: Discover 5 Top Point-of-Care (POC) Diagnostics Solutions Startups Read more June 8th, 2023 Hememics Biotechnologies, Inc. and General Graphene Corporation Cement Strategic Partnership for Large-Scale Production of Graphene-Based Biosensors Read more June 8th, 2023 Partnership to Mass-Produce Graphene Biosensors Read more June 7th, 2023 TEDCO Invests SSBCI Funding into Hememics Biotechnologies, Inc. Read more June 1st. 2023 Hememics to Showcase Rapid Point of Care Biosensor System at 2023 AACC Expo in Anaheim, CA Read more May 30th, 2023 Handheld Multiplexed Biosensor Platform Tests Antibodies, Antigens and Molecular Targets Simultaneously Read more May 26th, 2023 Gaithersburg diagnostic company Hememics Biotechnologies nabs millions ahead of larger funding round Read more May 25th. 2023 Hememics Biotechnologies Closes $2M Seed 2 Round Read more Next >

Go back Mary E. Schmidt, MD Board member President, Schmidt & Libby Health Advisory Group Associate Professor of Clinical Medicine, VCU Dr. Schmidt is the President of Schmidt and Libby Health Advisory Group. She is board-certified in infectious diseases and internal medicine, has a master’s degree in Public Health from John Hopkins Bloomberg School of Public Health, and is an associate professor of Clinical Medicine at Virginia Commonwealth University. She practiced her specialty of infectious diseases for 25 years and has many awards and honors including the Best Physicians in America. In addition, Dr. Schmidt has had several leadership positions. She was Chief of Staff at the Inova Fairfax Medical Campus from 2010 through 2013 where she led the quality and citizenship activities of 2,400 physicians. She was a member of the Command Center at Inova Fairfax Hospital for Disaster and Bioterrorism Events and a member of the Inova Health System Oversight Committee for the roll out of the Epic medical record system. Dr. Schmidt has also held the position of Director of Transplant Infectious Diseases for 6 years at Inova Fairfax Hospital where she focused on the medical care of immunocompromised individuals and excellence in the care of transplant patients. Previous Next

All News May 25th, 2023 Hememics Biotechnologies, Inc. Announces Successful Close in $2 Million Seed 2 Financing from TEDCO and Qualified Investors to Accelerate Growth Read more July, 2020 Biosensors for on-the-spot tests: Two companies plan to debut new tech for COVID-19 testing by year's end Read more July, 2020 U. S. cities pilot connected-vehicle tech: Enabling conventional vehicles to communicate could save lives right now Read more April 21, 2020 Company: New coronavirus test could diagnose the virus in 60 seconds or less Read more April 20, 2020 BARDA to work with Hememics on rapid COVID-19 test Read more April 16, 2020 Hememics’ rapid point-of-care COVID-19 test gets infusion from BARDA Read more April 16, 2020 HEMEMICS Biotechnologies, Inc. Receives HHS Support to Develop Rapid Antigen, Antibody Diagnostic to Identify COVID-19 Infected Americans Read more December 1, 2017 Inova Personalized Health Accelerator Accepts HeMemics Biotechnologies, Inc. into Portfolio Read more December 11, 2019 Hememics Biotechnologies Inc. Received $2.5 Million Investment from AMVI Partners Read more < Previous

Go back David Ho, PhD Board member & Founder Founder, President & CSO An acknowledged expert on blood platelets who has been at the forefront of blood research for over a decade. Dr. Ho is well-published and has expanded the understanding of how coagulation protein factor XI interacts with platelets. Inventor of an unique desiccation technique to preserve human cells for extended storage. He has been issued three US patents and numerous scientific awards. Has directed numerous inter-organizational projects with academic, government and industry partners for cellular products in wound dressing, tissue regeneration and transfusable applications. Previous Next

HemSol Buffer Solution Vitrification drying dehydration preservation buffer for biologically active materials ID: 230416 HemChip Disposable Biosensor With bioreceptor layer and proprietary biochip, designed to detect pathogens with utmost speed, accuracy, and sensitivity. ID: 230206 HemBox Biosensor Platform Reader A handheld environmentally resilient analytical device made for rapid on-site identification of bio-hazards present in water, soil, and infected persons. ID: 230716 Get Price Quote First name Email Last name Phone Select a Product Choose an option Give us more details I accept terms & conditions Request a Quote Thanks! We’ll send you a price quote shortly.

Go back Thomas S. Dann Board member Managing Director, Castlehaven Advisors, LLC Mr. Dann has almost 20 years’ experience in technology investing and company building. He was previously Managing Director of two early stage venture funds, the Maryland Venture Fund and ECentury Capital Partners. He also formerly served as a director of Global Internet Ventures, LLC and as Founder and Managing Director of Castlehaven Advisors, LLC. During his venture career, Mr. Dann served as a director of numerous early stage companies, as well as a Director of the Mid-Atlantic Venture Association. He received a B.A. degree from Stanford University and a Juris Doctorate from American University Law School. Previous Next

< Back Go back A Bit About David Ho, PhD Founder, President & CSO An acknowledged expert on blood platelets who has been at the forefront of blood research for over a decade. Dr. Ho is well-published and has expanded the understanding of how coagulation protein factor XI interacts with platelets. Inventor of an unique desiccation technique to preserve human cells for extended storage. He has been issued three US patents and numerous scientific awards. Has directed numerous inter-organizational projects with academic, government and industry partners for cellular products in wound dressing, tissue regeneration and transfusable applications. < Previous Next >

< Back Go back A Bit About Richard Liu CFO Extensive professional experiences in capital markets, financial analysis, accounting and auditing ​MBA from Johnson Graduate School of Management, Cornell University; BBA from Baruch College, City University of New York. He is a CFA Charterholder and was a CPA in New York State.​ Successfully oversaw equity trading desk with hundreds of millions of shares of trading volume in the US, EU, and Japan and brought direct positive impact to P&L by leveraging technology to improve execution speed and quality with lower commissions. < Previous Next >

Events Meet Us At July 28 - August 1 McCormick Place Convention Center Chicago, IL, USA Booth #4455 ADLM 2024 Association for Diagnostics & Laboratory Medicine Formerly the AACC Annual Scientific Meeting & Clinical Lab Expo July 23 - July 27 See you at the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo Anaheim Convention Center, Anaheim CA USA Booth # 951 View Pictures from the Event

Latest News July 20th, 2023 Global Startup Heat Map. Discover 5 Top Point-of-Care (POC) Diagnostics Startups Read More June 8th, 2023 Hememics Biotechnologies, Inc. and General Graphene Corporation Cement Strategic Partnership for Large-Scale Production of Graphene-Based Biosensors Read More June 7th, 2023 TEDCO Invests SSBCI Funding into Hememics Biotechnologies, Inc. Read More June 8th, 2023 Partnership to Mass-Produce Graphene Biosensors Read More June 1st, 2023 Hememics to Showcase Rapid Point of Care Biosensor System at 2023 AACC Expo in Anaheim, CA Read More May 25th, 2023 Hememics Biotechnologies Closes $2M Seed 2 Round Read More July, 2020 U. S. Cities Pilot Connected-Vehicle Tech: Enabling Conventional Vehicles to Communicate Could Save Lives Right Now Read More May 25th, 2023 Hememics Biotechnologies, Inc. Announces Successful Close in $2 Million Seed 2 Financing from TEDCO and Qualified Investors to Accelerate Growth Read More April 21, 2020 Company: New Coronavirus Test Could Diagnose The Virus in 60 Seconds or Less Read More July, 2020 Biosensors for On-The-Spot Tests: Two Companies Plan to Debut New Tech for COVID-19 Testing by Year's End Read More May 30th, 2023 Handheld Multiplexed Biosensor Platform Tests Antibodies, Antigens and Molecular Targets Simultaneously Read More VIEW ALL

< Back Go back A Bit About Srivatsa Aithal, PhD Director of R&D Sri Aithal pursued his Post-Doc at McMaster University and Ph.D. at Sherbrooke University in Canada. He drove the effort to commercialize impedance spectroscopy-based sensing at Abnova, Taiwan. He was also a Co-Founder of Celerite Labs, a startup company commercializing magnetic bio-printing technology that accelerated drug discovery. Sri has several journal publications and an approved patent. < Previous Next >

Privacy Policy Welcome to the Privacy Policy of Hememics ("we" or "us"). This Policy applies to all information collected by Hememics during your use of this website ("site"). We kindly request that you carefully read this information before accessing any part of the site. ​ Our Commitment to Your Privacy ​ At Hememics, we acknowledge and respect the privacy of our site users. In order to better protect your privacy, we have developed this Policy to explain our online information practices and how we collect and utilize information obtained from you. Please note that Hememics may update this Policy periodically without prior notice. You can access the most recent version of this Policy through the "Terms & Conditions of Use" link located at the bottom of every page on this site. General ​ Hememics may collect information about visitors to this site by tracking the usage of certain features available here. This information helps us tailor the content of the site to suit your needs and keep you informed about topics of interest. ​ Specifically, when you provide personally-identifiable information on this site, Hememics may collect it responsibly. This may include details such as your name, mailing address, telephone and/or facsimile number, email address, and other similar information. Hememics will handle your personally-identifiable information in a secure manner, utilizing both online and offline measures. This collection of personally-identifiable information enables Hememics to provide individuals with relevant information about Hememics products and services. We might share this information with our vendors and partners to tailors our offering to your needs. ​ Furthermore, Hememics may store and disclose personally-identifiable information as permitted or required by applicable law. We may make necessary disclosures to protect the rights, safety, or property of Hememics or others, comply with legal or regulatory requirements, or investigate and prevent violations of our Terms and Conditions. Except as mentioned above, Hememics will not disclose, sell, lease, or rent your personally-identifiable information. ​ Use of Cookies and Other Web Technologies ​ Cookies are small data text files that may be stored on your computer's hard drive if your web browser allows it. Most web browsers provide instructions on how to prevent the acceptance of new cookies, receive notifications when you receive a new cookie, or disable most cookies altogether. Even if you reject the use of cookies, you can still use this site. However, please note that by refusing to accept cookies, you may not be able to access certain tools and features offered on our site. ​ Cookies may be used by some of the websites we link to. Therefore, we encourage you to review the Links section of this Policy below. Additionally, we may use your Internet Protocol (IP) address to analyze trends, administer this site, and gather general demographic information in order to improve its functionality. On this site, we may use cookies to enhance navigation and perform the following functions: ​ Recognize your web browser as a returning visitor and remember any preferences set during your previous visits. Customize the content provided to you based on your apparent interests, as your web browser navigates the internet. Measure and research the effectiveness of our site's features, offerings, and email communications by determining which emails you open and engage with. ​ While we may use cookies to improve your navigation experience on this site, please be aware that some of the external websites we link to might also employ cookies. Therefore, we advise you to review the Links section of this Policy below. Additionally, we may use your Internet Protocol (IP) address to analyze trends, administer this site, and gather general demographic information to enhance its overall performance. We will not link any collected IP addresses to personally-identifiable information. ​ Automatic Information ​ As described above, we may automatically collect some information about your computer when you visit our sites. This data might include session data, including your IP address, web browser software, and referring site. We also may collect information about your online activity, such as content viewed and pages visited. We collect this automatic information to help us understand the interests of our customers and visitors and customize your user experience, among other things. ​ Our Commitment to Children's Privacy ​ Protecting the privacy of the very young is especially important. For that reason, Hememics does not intend to or knowingly collect or maintain personally-identifiable information from children under 13. Correcting or Retrieving Your Information ​ If your personally-identifiable information changes or if you no longer want Hememics to maintain your information, you can accomplish this by sending us an email at infomation@hememics.com or by sending your request to: ​ Hememics Biotechnologies, Inc 401 Professional Drive, Suite 220 Gaithersburg, MD 20879-3445 ​ Hememics will send a confirming email to your last known email address regarding the changes or deletion of your personally-identifiable information. ​ Contact Us ​ If you have any questions about this Policy or our site, please contact us at infomation@hememics.com .